Rui Ni is an associate professor in the Department of Mechanical Engineering at Johns Hopkins University, directing the Fluid Transport Lab. His research focuses on experimental fluid mechanics, turbulence, multiphase flows, and their applications in energy systems, environmental engineering, and physiological processes. He holds a PhD in Physics from the Chinese University of Hong Kong (2011), followed by postdoctoral work at Yale and Wesleyan Universities. Before joining JHU, he held the Kenneth Kuan-Yun Kuo Early Career Professorship at Penn State University. His research interests include dusty flows, Lagrangian particle tracking, and animal collective behaviors. Notable projects include collaborations with NASA on plume-surface interaction and the development of advanced diagnostic tools like physics-informed machine learning and 3D particle tracking. He has received prestigious awards, including the NSF CAREER Award and ACS-PRF New Investigator Award, and leads studies on turbulence modulation by deformable bubbles, fish schooling efficiency in turbulent environments, and interfacial mass transfer dynamics. Key Projects: Plume-Surface Interaction (NASA collaboration), Fish Aquarium with Turbulent Environment (FATE) facility, V-ONSET multiphase flow facility. Grants: Gordon and Betty Moore Foundation’s Experimental Physics Investigators Initiative Grant. Lab Focus: Experimental and computational studies of multiphase flows, physiological flows, and complex systems. Ni’s work bridges fundamental fluid dynamics with practical applications, such as improving energy efficiency and understanding biological systems like fish schooling and nasal drug delivery mechanisms.
Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award
Alanson Sample is an Associate Professor in the Department of Electrical Engineering and Computer Science at the University of Michigan (since 2018), leading the Interactive Sensing and Computing Lab. His research focuses on Human-Computer Interaction, Cyber-Physical Systems, and wireless technology innovations. He holds a PhD in Electrical Engineering from the University of Washington (2011), with prior postdoctoral work there developing implantable medical devices. Before academia, Sample held senior roles at Disney Research (2013-2018) as Executive Lab Director and Principal Research Scientist, leading teams in Robotics, AI, Computer Vision, and HCI. Earlier, he worked at Intel Labs (2008-2013) on energy harvesting for wearables and IoT. Key research themes include wireless power systems, embedded sensing, and privacy-aware technologies. Over 150+ publications span topics like magnetic sensing (MagDesk), acoustic gesture recognition (HandSAW), and privacy-preserving activity tracking (PrivacyMic). His work bridges academic and industry innovation, particularly in scalable interactive systems and medical technology. Notable projects include the Quasistatic Cavity Resonance wireless charging system, RFID-based sensing platforms (WISP), and wearable health monitoring devices. His lab develops hardware-software co-design frameworks for energy-efficient embedded systems. Current research emphasizes medical applications, smart infrastructure, and ubiquitous computing interfaces.
Allan Larsen is a Professor and Deputy Head of Division at the Department of Technology, Management and Economics (DTU Management) at the Technical University of Denmark. He heads the Operations and Supply Chain Management Section. His academic background includes an MSc in Applied Mathematics and a PhD in Operations Research, both from DTU. He teaches courses in Operations Management and Simulation at both undergraduate and graduate levels. Research Focus: His work applies operations research methodologies to complex planning problems in supply chain management, logistics, healthcare operations, and public transport. Key areas include urban freight transport, healthcare supply chains, and optimization of public transport resources like crew and fleets. Collaborations with industries, especially in freight transport, have been extensive. He previously co-directed the Transport DTU research center and co-chaired Denmark’s Transport Innovation Network. Education: MSc in Applied Mathematics (1989–1995), PhD in Operations Research (1997–1999), both from DTU. Recognition: Recipient of the Hedorf’s transportpris award in 2022 for contributions to transport research. Research Projects: Supervises multiple PhD students (e.g., on electric freight transport, healthcare resource optimization, and Industry 4.0 applications). Active in projects like 'Pioneering Electric Heavy-Duty Freight Transport' and 'Resource optimization in healthcare.' Labs/Teams: Leads the Operations and Supply Chain Management research group and collaborates in initiatives like the Transport Innovation Network, focusing on sustainable transport solutions.
Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Matthew L Becker is the Hugo L Blomquist Distinguished Professor of Chemistry at Duke University, with additional appointments in Mechanical Engineering and Material Science, and Biomedical Engineering. His research focuses on polymer chemistry, bioconjugate chemistry, molecular imaging, additive manufacturing, and degradable materials for bone, soft tissue, neural, and vascular tissue engineering. Education: B.S. from Northwest Missouri State University (1998), M.A. (2000) and Ph.D. (2003) from Washington University in St. Louis Research interests include developing tunable degradable polymers for flexible electronics, tissue engineering (bone, neural, vascular), and additive manufacturing. His group is pioneering 3D printing of bioresorbable medical devices and custom inks for biomaterials. Recent work explores stereochemistry-dependent polymer properties, mechanochromism, and machine learning-driven biomaterials design. Key applications: Drug delivery systems Biodegradable adhesives Tissue regeneration scaffolds Scientific honors include: Fellow, National Academy of Inventors (2022) Fellow, American Chemical Society (2020) Carl S. Marvel Award in Creative Polymer Chemistry (2019) Fellow, American Institute for Medical and Biomedical Engineering (2018) Fellow, Royal Society of Chemistry (2017) Biomacromolecules/Macromolecules Young Investigator Award (2015) He teaches advanced courses in mechanical engineering and polymer chemistry, with a focus on 3D printing and biomaterials. His group has developed novel medical devices including resorbable suture anchors, hernia mesh coatings, and neuroprosthetic scaffolds.
Dr. Rajesh Bera is a Research Fellow at ICFO's Functional Optoelectronic Nanomaterials group specializing in quantum-confined nanostructures. His research examines ultrafast carrier dynamics, excitonic properties, and optoelectronic applications of nanomaterials including quantum dots, nanoplatelets, and hybrid nanostructures. Current investigations focus on intraband transitions in doped nanocrystals, orientation-dependent excitonic behavior in 2D materials, and charge transfer mechanisms in heterostructure devices. Work bridges fundamental photophysics with applications in photodetection, sensing, and energy conversion. Recent publications demonstrate expertise in time-resolved spectroscopy of quantum materials, nanomaterial synthesis via colloidal chemistry, and rational design of optoelectronic devices. Continually develops novel characterization methods to probe ultrafast processes at nanoscale interfaces.
Burak Ozdoganlar is a Ver Planck Endowed Chair Professor of Mechanical Engineering at Carnegie Mellon University (CMU) and Associate Director of the Engineering Research Accelerator. He holds courtesy faculty positions in Biomedical Engineering and Materials Science and Engineering. Ozdoganlar earned his Ph.D. in Mechanical Engineering from the University of Michigan (1999), M.S. degrees from Ohio State University (1993, 1995), and a B.S. in Aeronautical Engineering from Istanbul Technical University (1991). Ph.D., Mechanical Engineering, University of Michigan (1999) MS, Mechanical Engineering, Ohio State University (1995) MS, Aeronautical and Astronautical Engineering, Ohio State University (1993) BS, Aeronautical Engineering, Istanbul Technical University (1991) Ozdoganlar’s research focuses on multi-scale manufacturing processes (macro/micro/nano), precision engineering , structural dynamics , and modal testing , with applications in biomedical device fabrication , microneedle arrays , soft electronics , and 3D ice printing for vascular networks. His work bridges computational modeling with experimental validation. Recent scientific awards include the 2023 AIMBE College of Fellows induction, ASME Fellow (2019), and NSF CAREER Award (2006). He served as interim CTO of the Advanced Robotics for Manufacturing (ARM) Institute and chaired the ASME-MED Manufacturing Equipment Technical Committee. Ozdoganlar leads projects in scalable manufacturing for implantable medical devices , bioelectric medicine , and wearable robotics . His lab develops 3D ice-printed vascular templates for tissue engineering and liquid metal circuits for soft electronics, funded by institutions like the Manufacturing Futures Institute and ARPA-H.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Hyun (Michel) Koo is a Professor at the University of Pennsylvania School of Dental Medicine , with affiliations in the Department of Orthodontics , Division of Community Oral Health , and Division of Pediatric Dentistry . As Co-Founder and Co-Director of the Center for Innovation & Precision Dentistry (CiPD) , he leads interdisciplinary efforts merging bioengineering, nanotechnology, and oral health research. Education : DDS and PhD Research Focus : Biofilms, bacterial-fungal interactions, and nanotechnology for oral disease prevention Leadership : Co-Director of CiPD; key roles in training programs like NIDCR-sponsored R90 and T90/R90 Dr. Koo’s research explores biofilm mechanisms in oral infectious diseases, particularly childhood caries, through engineering methods and microrobotics . His team developed micron-scale robots for automated biofilm eradication and FDA-approved nanoparticles for caries prevention. Collaborations with Penn Engineering, including Dr. Daeyeon Lee and Dr. Kacy Cullen, emphasize translational approaches. The 15 most recent publications highlight his work in nanorobotics , interkingdom biofilms , and precision diagnostics . Articles span 2025–2024 and address topics like adaptive micromotors , biofilm matrix degradation , and single-cell microbial interactions . These emphasize his focus on targeted therapies and biofilm microenvironment engineering . Key Awards : Elected Fellow, American Association for the Advancement of Science (AAAS) IADR Distinguished Scientist Award for innovative dental research Dr. Koo trains next-generation researchers through the CiPD NIDCR T90/R90 Postdoctoral Training Program , mentoring fellows like Smruti Nair (ACE2 Chewing Gum development) and Zhi Ren (K99 awardee). His work intersects with Penn Health-Tech, CT3N , and Penn Institute for Biomedical Informatics , fostering transdisciplinary innovation.
Dr. Kai Gong is an Assistant Professor of Civil and Environmental Engineering at Rice University, with affiliations at the Rice Advanced Materials Institute and Ken Kennedy Institute. His research focuses on sustainable infrastructure materials, environmental sustainability, and materials science. He holds a Ph.D. in Civil & Environmental Engineering and Materials Science from Princeton University, an MEngSci from Monash University (Australia), and dual B.S. degrees from Monash University and Central South University (China). Research Interests: Development of durable, sustainable infrastructure materials Waste encapsulation and conversion to value-added products Carbon mineralization and utilization Advanced characterization techniques (synchrotron/neutron scattering) Data-driven modeling and atomistic simulations Notable Awards: 2023 Le Chatelier Medal (Cement and Concrete Research) 2024 Giatec Award for Best Paper in Sustainability Walbridge Fund Graduate Award (2019) His work integrates computational methods (e.g., molecular dynamics) with experimental techniques to address decarbonization challenges in infrastructure. The Gong Research Group actively seeks motivated researchers for opportunities in sustainable materials innovation.
Christophe Meunier is a researcher specializing in hybrid materials, particularly focusing on biohybrid systems that integrate biological components with inorganic matrices. His work emphasizes environmental applications and biomedical innovations through advanced material design. Key Collaborations: Su, B. L., Michiels, C., Wang, L. Research Themes: Photosynthesis mimicry, cell therapy microcapsules, hybrid alginate-TiO₂ systems Research Focus: Meunier has pioneered the biomimicry of photosynthesis via biosystem immobilization in silica matrices, aiming to create 'living materials' with functional biological-inorganic interfaces. His recent projects explore alginate@TiO₂ hybrid microcapsules for controlled insulin delivery and cell therapy applications, demonstrating high biocompatibility and stability. Academic Contributions: With 34 research outputs spanning material science, biomedical engineering, and environmental applications, Meunier's work aligns with UN Sustainable Development Goals through innovative hybrid material design. His collaboration network includes experts in chemistry, physics, and medical fields.
Dr. Yogambha Ramaswamy is a Senior Lecturer in the School of Biomedical Engineering at The University of Sydney and a member of the Sydney Nano Institute. She holds a Master’s in Biotechnology from the University of Queensland and a PhD in Biomedical Engineering from the University of Sydney (2009). Her postdoctoral career began as a Vice-Chancellor’s Postdoctoral Research Fellow at the University of New South Wales, followed by a Peter Doherty Early Career Fellowship in 2013 before joining the University of Sydney in 2015. Dr. Ramaswamy’s research focuses on biomaterials, tissue engineering, and mechanobiology, with a particular emphasis on developing calcium silicate-based ceramics and biopolymers for orthopedic and regenerative applications. Her recent work explores the role of physical cues in modulating stem and cancer cell behavior. She teaches courses such as AMME1961 (Introduction to Biomedical Engineering B) and AMME5962 (Introduction to Mechanobiology). Her research has been supported by grants including the NHMRC Early Career Fellowship and collaborations with institutions like the CSIR-Indian Institute of Chemical Technology and the University of Otago. Her publications span biomaterials, nanotechnology, and mechanobiology, with recent work addressing atherosclerosis, hydrogel design, and nanomedicine. She currently supervises PhD students Frank (biomaterials) and Alexander (atherosclerosis research).
